Simplified Quantification of 11C-UCB-J PET Evaluated in a Large Human Cohort

Visual Abstract 11C-UCB-J ((R)-1-((3-(11C-methyl-11C)pyridin-4-yl)methyl)-4-(3,4,5-trifluorophenyl)pyrrolidin-2-one) is a PET tracer for synaptic vesicle glycoprotein 2A, which may be a marker of synaptic density. To simplify the scan protocol, SUV ratios (SUVRs) were compared with model-based nondisplaceable binding potential (BPND) to select the optimal time window in healthy and neuropsychiatric subjects. Methods: In total, 141 scans were acquired for 90 min. Arterial blood sampling and metabolite analysis were conducted. SUVR-1 (centrum semiovale reference region) was computed for six 30-min windows and compared with 1-tissue-compartment model BPND. Simulations were performed to assess the time dependency of SUVR-1. Results: Greater correlation and less bias were observed for SUVR-1 at later time windows for all subjects. Simulations showed that the agreement between SUVR-1 and BPND is time-dependent. Conclusion: The 60- to 90-min period provided the best match between SUVR-1 and BPND (−1% ± 7%); thus, a short scan is sufficient for accurate quantification of 11C-UCB-J–specific binding.

[1]  Richard E Carson,et al.  Assessment of a white matter reference region for 11C-UCB-J PET quantification , 2020, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[2]  Peter Herscovitch,et al.  Comparison of Bolus and Infusion Methods for Receptor Quantitation: Application to [18F]Cyclofoxy and Positron Emission Tomography , 1993, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[3]  Xiao Jin,et al.  Evaluation of motion correction methods in human brain PET imaging--a simulation study based on human motion data. , 2013, Medical physics.

[4]  Yiyun Huang,et al.  Kinetic evaluation and test–retest reproducibility of [11C]UCB-J, a novel radioligand for positron emission tomography imaging of synaptic vesicle glycoprotein 2A in humans , 2017, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[5]  Dustin Scheinost,et al.  Lower synaptic density is associated with depression severity and network alterations , 2019, Nature Communications.

[6]  Koen Van Laere,et al.  Quantifying SV2A density and drug occupancy in the human brain using [11C]UCB-J PET imaging and subcortical white matter as reference tissue , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[7]  R. Carson,et al.  PET physiological measurements using constant infusion. , 2000, Nuclear medicine and biology.

[8]  D. Spencer,et al.  Imaging synaptic density in the living human brain , 2016, Science Translational Medicine.

[9]  Richard E Carson,et al.  Assessing Synaptic Density in Alzheimer Disease With Synaptic Vesicle Glycoprotein 2A Positron Emission Tomographic Imaging , 2018, JAMA neurology.

[10]  S. DeKosky,et al.  Kinetic Modeling of Amyloid Binding in Humans using PET Imaging and Pittsburgh Compound-B , 2005, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[11]  Yiyun Huang,et al.  Synaptic Changes in Parkinson Disease Assessed with in vivo Imaging , 2020, Annals of neurology.

[12]  Richard E Carson,et al.  Synthesis and Preclinical Evaluation of 11C-UCB-J as a PET Tracer for Imaging the Synaptic Vesicle Glycoprotein 2A in the Brain , 2016, The Journal of Nuclear Medicine.